Induction of apoptosis by vinblastine via c-Jun autoamplification and p53-independent down-regulation of p21

Molecular Pharmacology

Volumn 73, Issue 1, 2008, Pages 128-136

  Kolomeichuk, Sergey N ^a   Bene, Anca ^a   Upreti, Meenakshi ^a   Dennis, Richard A ^b   Lyle, Christopher S ^a   Rajasekaran, Maheswari ^a   Chambers, Timothy C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; DACTINOMYCIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROTEIN P53; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA TRANSCRIPTION; RNA TRANSLATION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 37349024831     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.039750     Document Type: Article

References (36)

1. Angel P, Hattori K, Smeal T, and Karin M (1988) The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55:875-885.
2. Bene A, Kurten RC, and Chambers TC (2004) Subcellular localization as a limiting factor for utilization of decoy oligonucleotides. Nucleic Acids Res 32:e142.
3. Berry A, Goodwin M, Moran CL, and Chambers TC (2001) AP-1 activation and altered AP-1 composition in association with increased phosphorylation and expression of specific Jun and Fos family proteins induced by vinblastine in KB-3 cells. Biochem Pharmacol 62:581-591.
4. Bhalla KN (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086.
5. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, Szwedo D, Kaushal GP, and Chambers TC (2003) The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66:459-469.
6. Casenghi M, Mangiacasale R, Tuynder M, Caillet-Fauqet P, Elhajouji A, Lavia P, Mousset S, Kirsch-Volders M, and Cundari E (1999) p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp Cell Res 250:339-350.
7. WAF1/C1P1-mediated G2/M arrest in a p53-deficient human lung cancer cell. Biochem Biophys Res Commun 293:1248-1253.
8. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
9. de Belle I, Mercola D, and Adamson ED (2000) Method for cloning in vivo targets of the Egr-1 transcription factor. Biotechniques 29:162-169.
10. Devi GR (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther 13:819-829.
11. Du L, Lyle CS, and Chambers TC (2005) Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24:107-117.
12. Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, and Chambers TC (2007) Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol 73:481-490.
13. Fan M and Chambers TC (2001) Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Update 4:253-267.
14. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA, and Chambers TC (2000) Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275:29980-29985.
15. 2-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 61:4450-4458.
16. Fuchs SY, Fried VA, and Ronai Z (1998) Stress-activated kinases regulate protein stability. Oncogene 17:1483-1490.
17. Gartel AL and Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65:3980-3985.
18. Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C, Omichi M, McClelland M, and Mercola D (2004) Identification of promoters bound by c-Jun/ ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 16:521-535.
19. Jordan MA and Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265.
20. WAF1/Cip1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem 274:29572-29581.
21. Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486.
22. Khan SH and Wahl GM (1998) p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58:396-401.
23. Mollinedo F and Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413-450.
24. Obey TB, Lyle CS, and Chambers TC (2005) Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine. Biochem Biophys Res Commun 335:1179-1184.
25. 2-terminal protein kinase pathway in the cellular response to Adriamycin and other chemotherapeutic drugs. J Biol Chem 271:30950-30955.
26. Rowinsky EK and Donehower RC (1998) Microtubule-targeting drugs, in The Chemotherapy Source Book (Perry MC ed) pp 387-423, Lippincott Williams & Wilkins, Baltimore.
27. Ruvolo PP, Deng X, and May WS (2001) Phosphorylation of Bcl-2 and regulation of apoptosis. Leukemia 15:515-522.
28. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, and Wagner EF (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13:607-619.
29. CIP1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734.
30. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, and Karin M (2000) The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 103:897-8907.
31. Stennicke HR and Salvesen GS (2000) Caspase assays. Methods Enzymol 322:91-100.
32. Stone AA and Chambers TC (2000) Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 254:110-119.
33. Tsao YP, Li LY, Tsai TC, and Chen SL (1996) Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes. J Virol 70:7535-7539.
34. van Dam H, Duyndam M, Rottier R, Bosch A, de Vries-Smits L, Herrlich P, Zantema A, Angel P, and van der Eb AJ (1993) Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J 12:479-487.
35. Wang CH, Tsao YP, Chen HJ, Chen HL, Wang HW, and Chen SL (2000) Transcriptional repression of p21((Waf1/Cip1/Sdi1)) gene by c-Jun through Sp1 site. Biochem Biophys Res Commun 270:303-310.
36. 2/M. Mol Cel Biol 19:8469-8478.